0001562180-22-007125.txt : 20221007 0001562180-22-007125.hdr.sgml : 20221007 20221007160522 ACCESSION NUMBER: 0001562180-22-007125 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221006 FILED AS OF DATE: 20221007 DATE AS OF CHANGE: 20221007 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Katkin Keith CENTRAL INDEX KEY: 0001314596 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37708 FILM NUMBER: 221300802 MAIL ADDRESS: STREET 1: C/O UROVANT SCIENCES, INC. STREET 2: 5281 CALIFORNIA AVENUE, SUITE 100 CITY: IRVINE STATE: CA ZIP: 92617 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Syndax Pharmaceuticals Inc CENTRAL INDEX KEY: 0001395937 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 320162505 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 GATEHOUSE DRIVE STREET 2: BUILDING D, FLOOR 3 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-419-1400 MAIL ADDRESS: STREET 1: 35 GATEHOUSE DRIVE STREET 2: BUILDING D, FLOOR 3 CITY: WALTHAM STATE: MA ZIP: 02451 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2022-10-06 false 0001395937 Syndax Pharmaceuticals Inc SNDX 0001314596 Katkin Keith C/O SYNDAX PHARMACEUTICALS, INC. 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3 WALTHAM MA 02451 true false false false Common Stock 2022-10-06 2022-10-06 4 M false 20782.00 7.88 A 52782.00 D Common Stock 2022-10-06 2022-10-06 4 S false 20782.00 25.9009 D 32000.00 D Common Stock 2022-10-06 2022-10-06 4 M false 9117.00 8.93 A 41117.00 D Common Stock 2022-10-06 2022-10-06 4 S false 9117.00 25.9009 D 32000.00 D Stock Options (Right to buy) 8.93 2022-10-06 4 M false 9117.00 0.00 D 2028-05-23 Common Stock 9117.00 0.00 D Stock Options (Right to buy) 7.88 2022-10-06 4 M false 20782.00 0.00 D 2029-06-10 Common Stock 20782.00 0.00 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 73,000 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested. The sale prices ranged from $25.0000 to $26.4600. This option is fully vested. /s/ Michael A. Metzger, as Attorney-in-Fact 2022-10-07